Pharmaxis Europe Patent-Cliff Exposure & CMS Drug Spending Portfolio

Pharmaxis Europe (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $250K 2024 CMS Part D & Medicaid spend, and $3,656 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$250K
2024 Medicare Part D Spend$126K
2024 Medicaid Spend$124K
California HCAI SB 17 FilingsSpecialty launch notice ($3,656 intro WAC)